文献速递浆细胞疾病

美氟芬联合地塞米松治疗重度经治复发难治多发性骨髓瘤

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2020-12-09

II期HORIZON试验评估美氟芬联合地塞米松治疗对泊马度胺和/或抗CD38单抗耐药的复发难治多发性骨髓瘤。157例患者(中位年龄65岁,中位既往5线治疗)总缓解率29%,三代耐药人群26%,中位无进展生存4.2个月,中位总生存11.6个月。安全性可控,常见≥3级不良事件为中性粒细胞减少、血小板减少和贫血。

要点

  • 美氟芬联合地塞米松在重度经治RRMM中总缓解率29%,三代耐药人群26%
  • 中位无进展生存4.2个月,中位总生存11.6个月,中位缓解持续时间5.5个月
  • ≥3级不良事件发生率高(96%),以血液学毒性为主,但安全性总体可控

核心结论

  • 美氟芬联合地塞米松在重度经治复发难治多发性骨髓瘤中显示出有临床意义的疗效和可控的安全性。

研究设计与样本

  • II期HORIZON试验,纳入157例对泊马度胺和/或抗CD38单抗耐药的复发难治多发性骨髓瘤患者。
  • 美氟芬40 mg静脉注射第1天,每28天周期,联合地塞米松40 mg每周口服(>75岁者20 mg)。
  • 主要终点为研究者评估并经独立审查确认的总缓解率(部分缓解及以上)。

主要发现

  • 全治疗人群总缓解率29%,三代耐药人群26%。
  • 中位随访14个月时,全治疗人群中位缓解持续时间5.5个月,中位无进展生存4.2个月,中位总生存11.6个月。
  • 157例患者中位年龄65岁,中位既往5线治疗;119例(76%)为三代耐药,55例(35%)伴髓外病变,92例(59%)对既往烷化剂耐药。

关键数值与推荐

  • 总缓解率定义为部分缓解或更好,由研究者评估并经独立审查确认。
  • ≥3级治疗中出现的不良事件发生于96%患者,最常见中性粒细胞减少(79%)、血小板减少(76%)、贫血(43%)。
  • 最常见的3/4级非血液学不良事件为肺炎(10%)。
  • 胃肠道事件见于97例(62%),主要为1/2级(93%),无4级事件。

临床怎么用

  • 对于对泊马度胺和/或抗CD38单抗耐药的重度经治复发难治多发性骨髓瘤患者,可考虑美氟芬联合地塞米松方案。
  • 治疗期间需密切监测血液学毒性,尤其是中性粒细胞减少和血小板减少。
  • 需注意感染(如肺炎)和胃肠道不良事件的管理。

局限性

  • 为单臂II期试验,无随机对照,结论需进一步验证。
  • 样本量有限(157例),长期随访仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. PATIENTS AND METHODS: Patients with RRMM refractory to pomalidomide and/or an anti-CD38 monoclonal antibody received melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years). The primary end point was overall response rate (partial response or better) assessed by the investigator and confirmed by independent review. Secondary end points included duration of response, progression-free survival, overall survival, and safety. The primary analysis is complete with long-term follow-up ongoing. RESULTS: Of 157 patients (median age 65 years; median five prior lines of therapy) enrolled and treated, 119 patients (76%) had triple-class-refractory disease, 55 (35%) had extramedullary disease, and 92 (59%) were refractory to previous alkylator therapy. The overall response rate was 29% in the all-treated population, with 26% in the triple-class-refractory population. In the all-treated population, median duration of response was 5.5 months, median progression-free survival was 4.2 months, and median overall survival was 11.6 months at a median follow-up of 14 months. Grade ≥ 3 treatment-emergent adverse events occurred in 96% of patients, most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (43%). Pneumonia (10%) was the most common grade 3/4 nonhematologic event. Thrombocytopenia and bleeding (both grade 3/4 but fully reversible) occurred concomitantly in four patients. GI events, reported in 97 patients (62%), were predominantly grade 1/2 (93%); none were grade 4. CONCLUSION: Melflufen plus dexamethasone showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated RRMM, including those with triple-class-refractory and extramedullary disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Richardson PG, Oriol A, Larocca A, et al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2020. PMID: 33296242. doi:10.1200/JCO.20.02259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。